Funded Tech Companies
OncoMed Pharmaceuticals
Wondering who invested in OncoMed Pharmaceuticals? Bayer, De Novo Ventures and GlaxoSmithKline joined the equity holders in this innovative biopharmaceutical company.
Company Overview
Company Name
OncoMed Pharmaceuticals
Company Status
Publicly-held
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
800 Chesapeake Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Company Background Information
Overview
OncoMed Pharmaceuticals (NASDAQ: OMED) is discovering and developing monoclonal antibodies and small molecules capable of destroying cancer stem cells, a recently discovered type of cell believed to seed the growth of cancers and underlie cancer's ability to spread and take root in tissues.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
7/18/2013
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Lewicki
Chief Scientific Officer
Austin Gurney
Vice President
Ann Kapoun
VP - Finance
Yvonne Li
VP - General Counsel
Alicia Hager
VP - R & D
Robert Stagg
VP - Regulatory Affairs
Jill Henrich
Company Investors
- Bayer
- De Novo Ventures
- GlaxoSmithKline
- Morgenthaler Ventures (James Broderick)
- U.S. Venture Partners (Jonathan Root)
- The Vertical Group (Jack Lasersohn)
- Latterell Venture Partners (James Woody)
- De Novo Ventures (Frederick Dotzler)
- Adams Harkness Ventures (Terry Gould)
- Bay Partners (Atul Kapadia)
- Morgenthaler Ventures (Paul Hastings)
- Latterell Venture Partners (Laurence Lasky)
Browse more funded tech companies:
OncologyPro | OncoMyx Therapeutics
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs